EUSA Pharma has completed its $115 million acquisition of the global Sylvant rights from Janssen.
Sylvant (siltuximab) is approved in more than 40 countries for the treatment of idiopathic multicentric Castleman’s disease (iMCD).
It is the only treatment approved in the US and Europe for this condition.
EUSA said it intends to commercialise Sylvant through its worldwide commercial platform, which it plans to expand further into a number of new markets.
EUSA is currently planning to invest in developing Sylvant in additional indications where IL-6 blockade may be indicated.
Among these, the company is looking into Cytokine Release Syndrome associated with CAR-T therapy
“Sylvant is a perfect fit with EUSA’s oncology and rare disease focus and provides the company with a major opportunity to continue its rapid growth,” said EUSA CEO Lee Morley.
“As the only approved treatment for the devastating disorder iMCD, we have ambitious plans to bring Sylvant to patients around the world.
“As part of this strategy we plan to use our established commercial platform in Europe, develop new commercial operations in a number of new territories, and leverage our significantly expanded US commercial team to relaunch Sylvant in the United States.
“We are also excited to begin clinical development in new indications with high unmet need, as part of our plans to enable as many patients as possible to benefit from Sylvant.”